Abstract:
Patients with chronic hepatitis-B-virus (HVB) infection may exhibit significant liver pathology despite alanine aminotransferase (ALT) and HBV-DNA levels below current treatment guideline's cut-off values. This study evaluated the candidacy for HBV therapy if baseline histopathological changes
.
Third, predominant HBV genotype D [3] , which is more often associated with HBeAg-negative variants [6] and more severe liver disease [7] . This HBeAg negative disease is characterized by persistent viral replication, progression of liver disease, and early development of cirrhosis [8, 9] . The available HBV treatment guidelines are almost similar [10] [11] [12] [13] , despite geographical differences in epidemiology of the disease [14] .
According to the American Association [11, 13] . ALT and HBV-DNA levels do fluctuate necessitating their frequent monitoring or performing liver biopsy to assess disease activity, grade of fibrosis, and the eligibility for treatment [13] . Additionally, the REVEAL study has indicated that patients with HBVDNA<2,000 IU/ml are also at risk of disease progression [15] . Moreover, assessing liver histopathology was advised by the AASLD for evaluation of histologic disease in chronic HBV patients presenting with normal ALT and low HBV-DNA levels [11] . Therefore, the main objective of this study in patients with chronic HBV infection were to evaluate whether incorporation of liver histopathological changes and
(35)
HBV genotype affects the decision to treat both HBeAg-negative and HBeAg positive patients and influence the candidacy to treat such patients compared to the current strategies that rely mainly on both serum ALT and HBV-DNA levels.
Patients and Methods

Patients
A total of 592 patients with chronic HBV infection attending our hepatology outpatient clinic from May 2011 to May 2015 were included. 
Exclusion criteria
Laboratory tests
Routine liver biochemical tests were performed using commercially available auto-analyzers and hepatitis serological markers were assayed using commercially available enzyme-linked immunoassays (Clinotech Diagnostics).
According to the instructions of the manufacturer, the ULN for ALT was determined to be 40 U⁄ml (Bicon were considered to have significant pathology.
Statistical analyses:
Data were collected initially in a variables with skewed distribution was tested by Spearman'srank correlation.
Results
Baseline patients' characteristics
As shown in tab. (1) Moderate-to-severe inflammation (≥A2) was detected in 74 (46.0 %) patients and significant fibrosis (≥F2) was found in (37) 
Comparison between HBeAg negative and HBeAg positive patients
As shown in tab. 
Relation between the HBV-DNA and liver histopathology
There was a significant weak 
Relation between the ALT level and liver histopathology
There 
Candidacy to treatment decision
Based on serum HBV-DNA (>2000 iu/mL or >20000 iu/mL according Egypt [3, 22] . Unfortunately, this genotype is known to be associated with the HBeAg-negative variant [6] , and with more severe liver disease [7] . Therefore, 
Conclusion
Liver 
